Literature DB >> 9052994

Alpha 2a-interferon-induced differentiation of human alveolar rhabdomyosarcoma cells: correlation with down-regulation of the insulin-like growth factor type I receptor.

R Thulasi1, P Dias, P J Houghton, J A Houghton.   

Abstract

Rhabdomyosarcoma, a tumor of skeletal muscle origin, appears developmentally arrested at an early stage in the myogenic differentiation pathway. The proliferation of an alveolar rhabdomyosarcoma cell line Rh30 is dependent on the insulin-like growth factor (IGF) II/IGF-I receptor (IGF-IR) signaling pathway and is highly sensitive to recombinant human IFN-alpha 2a, which induces growth arrest and differentiation of these malignant myoblasts. IFN-alpha 2a-induced growth arrest of Rh30 cells was observed within 48 h, and reduction in colony formation was obtained with an IC50 of 0.81 IU/ ml for 72 h exposure. Down-regulated expression of IGF-IR was apparent by 24 h after initiation of IFN-alpha 2a treatment. Furthermore, an initial increase followed by reduced expression of MyoD, in concert with elevated expression of myogenin, increased frequency of skeletal muscle myosin-positive cells, and the formation of multinucleated cells, indicated an enhancement of differentiation of Rh30 cells in the presence of IFN-alpha 2a. To probe the role of IGF-IR in the differentiation of Rh30 cells along the myogenic lineage, the effect of antisense RNA-mediated reduction of endogenous IGF-IR on growth and expression of muscle-specific proteins was determined. Rh30 cells transfected to stably express antisense IGF-IR (clone AS [symbol: see text] 23)showed significant reduction in growth rate, decreased expression of IGF-IR protein, increased expression of MyoD, myosin heavy chain, and an increased number of multinucleated cells in comparison to the parental line. These data are consistent with overexpression of IGF-IR inhibiting differentiation. IFN-alpha 2a treatment of AS [symbol: see text] 23 cells further induced both MyoD and myogenin expression, thereby allowing cells to proceed further downstream of the differentiation pathway.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9052994

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  6 in total

1.  The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal.

Authors:  M Prisco; A Hongo; M G Rizzo; A Sacchi; R Baserga
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

2.  Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors.

Authors:  R Bagatell; C E Herzog; T M Trippett; J F Grippo; G Cirrincione-Dall; E Fox; M Macy; J Bish; P Whitcomb; A Aikin; G Wright; S Yurasov; F M Balis; L Gore
Journal:  Clin Cancer Res       Date:  2010-12-02       Impact factor: 12.531

3.  Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells.

Authors:  P L Puri; Z Wu; P Zhang; L D Wood; K S Bhakta; J Han; J R Feramisco; M Karin; J Y Wang
Journal:  Genes Dev       Date:  2000-03-01       Impact factor: 11.361

4.  Overexpression of the skNAC gene in human rhabdomyosarcoma cells enhances their differentiation potential and inhibits tumor cell growth and spreading.

Authors:  Janine Berkholz; Weronika Kuzyniak; Michael Hoepfner; Barbara Munz
Journal:  Clin Exp Metastasis       Date:  2014-09-11       Impact factor: 5.150

5.  Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives.

Authors:  Ana Sofia Martins; David Olmos; Edoardo Missiaglia; Janet Shipley
Journal:  Sarcoma       Date:  2011-03-03

6.  The role of insulin-like growth factor system in soft tissue sarcomas: from physiopathology to targeted therapeutic approaches.

Authors:  W Zumkeller
Journal:  Sarcoma       Date:  1998
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.